A phase III, randomized, placebo-controlled, double-blind clinical trial to investigate the efficacy and safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (hot flashes) in women with hormone receptor-positive breast cancer, stage 0 to 3, receiving adjuvant endocrine therapy.